Research Paper: Effect of Epigallocatechin Gallate and Catechin on Overexpression of GSK-3β and IR Genes Induced by Streptozotocin in Rat Brain

Marzieh Zamani1, Kambiz Rohampour1*, Samira Rashtiani1, Masoume Dolati1, Faranak Fallahian1, Naser Kalhor4

1. Department of Physiology, School of Medicine, Neuroscience Research Center, Guilan University of Medical Sciences, Rasht, Iran
2. Student Research Committee, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
3. Cellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran
4. Highly Specialized Jihad Daneshgahi Infertility Center, Qom University of Medical Sciences, Qom, Iran

Background: Type 2 Diabetes Mellitus (T2DM) is one of the significant risk factors for Alzheimer Disease (AD). Defects in insulin signaling pathway induce AD hallmarks mainly through activation of Glycogen Synthase Kinase-3β (GSK-3β) pathway.

Objectives: In this study, we investigated the expression of GSK-3β and Insulin Receptor (IR) genes in the hippocampus of an animal model of sporadic AD and assessed the preventive effect of Catechin (CAT) and Epigallocatechin Gallate (EGCG) on their expression.

Materials & Methods: Adult male Wistar rats were treated by intracerebroventricular Streptozotocin (STZ) injection (3 mg/kg) at day 1 and 3 after cannulation. CAT was administered at a dose of 40 mg/kg for 10 days per gavage, and EGCG was administered at a dose of 3 mg/kg for 14 days into drinking water. Then the animals were decapitated, and their hippocampi were removed. Real-time Polymerase Chain Reaction (PCR) was used to evaluate the alteration in gene expression.

Results: There was overexpression in GSK-3β gene in STZ-treated rats (P≤0.05), which was brought back to normalcy by EGCG (P≤0.01). The IR gene also increased after STZ treatment, but CAT reduced IR expression (P≤0.05). However, the suppressive effect of EGCG on IR expression was stronger (P≤0.01).

Conclusion: The neuroprotective activity of EGCG might be due to its influence on IR and GSK-3β expression.

Keywords: Catechin; Alzheimer disease; Receptor Insulin; Glycogen synthase kinases; Memory

ABSTRACT

Background: Type 2 Diabetes Mellitus (T2DM) is one of the significant risk factors for Alzheimer Disease (AD). Defects in insulin signaling pathway induce AD hallmarks mainly through activation of Glycogen Synthase Kinase-3β (GSK-3β) pathway.

Objectives: In this study, we investigated the expression of GSK-3β and Insulin Receptor (IR) genes in the hippocampus of an animal model of sporadic AD and assessed the preventive effect of Catechin (CAT) and Epigallocatechin Gallate (EGCG) on their expression.

Materials & Methods: Adult male Wistar rats were treated by intracerebroventricular Streptozotocin (STZ) injection (3 mg/kg) at day 1 and 3 after cannulation. CAT was administered at a dose of 40 mg/kg for 10 days per gavage, and EGCG was administered at a dose of 3 mg/kg for 14 days into drinking water. Then the animals were decapitated, and their hippocampi were removed. Real-time Polymerase Chain Reaction (PCR) was used to evaluate the alteration in gene expression.

Results: There was overexpression in GSK-3β gene in STZ-treated rats (P<0.05), which was brought back to normalcy by EGCG (P<0.01). The IR gene also increased after STZ treatment, but CAT reduced IR expression (P<0.05). However, the suppressive effect of EGCG on IR expression was stronger (P<0.01).

Conclusion: The neuroprotective activity of EGCG might be due to its influence on IR and GSK-3β expression.

Keywords: Catechin; Alzheimer disease; Receptor Insulin; Glycogen synthase kinases; Memory

* Corresponding Author:
Kambiz Rohampour
Address: Department of Physiology, School of Medicine, Neuroscience Research Center, Guilan University of Medical Sciences, Rasht, Iran
Tel: +98 (912) 4358587, Fax: +98 (13) 33690036
E-mail: rohampour@gums.ac.ir
Introduction

Around the world, 35.6 million people have dementia [1]. The most common form of dementia is Alzheimer Disease (AD) characterized by the accumulation of Amyloid-beta (Aβ) plaques, and its cardinal symptoms include language breakdown, memory loss, and cognitive impairment [2]. The pathological features of AD are intracellular Neurofibrillary Tangles (NFT) composed of hyperphosphorylated tau protein and extracellular accumulation of neurotic plaques comprising misfolded amyloid peptides [3].

Many reports indicate that oxidative stress is high in the brain of patients with AD or mild cognitive impairment [4]. Oxidative stress may be the first sign in the brain of patients with AD, which appears before Aβ deposition [5-7]. Transgenic mice bearing a mutant Amyloid Precursor Protein (APP) also show the primary presence of oxidative stress before Aβ deposition [8]. Evidence suggests that cells try to protect themselves from oxidative stress by secretion and deposition of Aβ plaques in vulnerable neurons [9]. Abnormal metabolism of APP and Aβ in mitochondria will damage the mitochondrial function by increasing Reactive Oxygen Species (ROS) and decreasing Adenosine Triphosphate (ATP) production [10]. Specifically, secretion of Aβ (to sequester ROS) eventually destroys cellular integrity; the peptide becomes subject to oxidative damage that causes its oligomerization and aggregation, which in turn produces neuroinflammation [11, 12]. Other consequences of cellular oxidative damage include cell cycle aberration and tau hyperphosphorylation, leading to the formation of NFTs [13, 14].

Catechin (CAT) is a polyphenolic flavonoid which has neuroprotective effects against oxidative stress [15]. Recently, this class of antioxidants has drawn attention because of their benefits, especially in the prevention and treatment of cancer, as well as cardiovascular, inflammatory, and neurodegenerative diseases [16, 17]. Some reports claim that CAT protects cultured mesencephalic neurons against 6-hydroxydopamine (6-OHDA) treatment and also prevents primary hippocampal neurons from Aβ toxicity [18, 19]. Evidence suggests that damages caused by Aβ can be undermined by antioxidants or polyphenols [20]. Epigallocatechin-3-Gallate (EGCG), the most abundant CAT in tea, also has neuroprotective effects. Some reports argue that CATs are more effective than vitamin E and C in the destruction of free radicals [21]. These antioxidants could be the primary candidates for the prevention and treatment of AD.

In this study, we evaluated the effects of CAT as a potent antioxidant on insulin signaling cascade. Notably, we examined whether CAT and EGCG could affect the hippocampal expression of insulin receptor (IR) and GSK-3β genes as potential signaling pathways involved in AD pathogenesis.

Materials and Methods

Animals

Adult male Wistar rats (weight: 250-300 g) were obtained from the Pasteur Institute of Iran. Rats were housed four animals per cage at a temperature-controlled room (22±2°C), with a 12-12 hour light-dark cycle. Rats had access to food and water ad libitum. Efforts were made to minimize animal suffering and the number of animals used. All studies were performed following the ethical guidelines of the “Ethics Committee of Faculty of Medicine, Qom University of Medical Sciences”, which
were based on the “NIH Guide for the Care and Use of Laboratory Animals.”

**Experimental procedure**

Rats were divided into 5 groups (n=3 for each group): Intact, CAT, Streptozotocin (STZ), STZ+CAT, and STZ+EGCG. The STZ group received 3 mg/kg Intracerebroventricular (ICV) STZ. The CAT group received 40 mg/kg CAT by daily gavage for 10 days. STZ+CAT group received CAT after the first ICV STZ injection by gavages for 10 days, and in the STZ+EGCG group, after the first ICV STZ injection, the EGCG was administered 3 mg/kg for 14 days into drinking water. This dose of CAT prevents oxidative stress and can reverse oxidative markers in the liver and kidney [27].

**Surgical procedure**

Rats were anesthetized with a mixture of ketamine (80 mg/kg, Intraperitoneally IP) and xylazine (20 mg/kg, IP) and were bilaterally implanted with cannulae (23-gauge) in the lateral ventricles with the following coordinates; AP: -0.8 mm from Bregma, ML: ±1.5 mm from midline and Dorsoventral (DV): -2.6 mm from the skull surface according to the atlas of Paxinos and Watson [28]. Two screws were inserted into the skull, and the cannulae fixed to them with dental cement. Three days after the operation, the rats received ICV STZ by an injection needle.

**Microinjection procedure**

Intracerebroventricular injections were made via guide cannulae with injection needles (30-gauge) that were connected by polyethylene tubing to a 10 μL Hamilton microsyringe. The injections (5 μL per site) were delivered over 2 min, and the injection needles (extending 1 mm from the end of the guide cannulae) were left in place an additional 3 min before they were slowly withdrawn. On days 1 and 3, after the surgery, the animals received 5 μL per site, vehicle Artificial Cerebrospinal Fluid (aCSF), or 3 mg/kg STZ dissolved in aCSF.

**Gene expression assay using a quantitative polymerase chain reaction**

All animals were decapitated, and their brains were incubated in chilled aCSF. The total Ribonucleic Acid (RNA) was extracted from hippocampus samples using the TRizol reagent (Invitrogen Technology, Carlsbad, CA, USA) according to the manufacturer’s protocol and stored at 80°C until further use. The RNA concentration was quantified by Ultra Violet (UV) spectrophotometer at 260 nm, and its purity and integrity were determined using the A260/A280 ratio. Total RNA was treated with DNase and then reverse transcribed into the first-strand cDNA in a 20 μL reaction volume using RevertAid M-MuLV Reverse Transcriptase, according to the manufacturer’s protocol (Vivantis Inc, Malaysia).

Quantitative Real-time Polymerase Chain Reaction (RT-PCR) assays of GSK-3β and IR cDNA were carried out using the SYBR Green kit (Qiagen, Inc.) in an Applied Biosystems (ABI) 7500 Sequence Detection System in accordance with the manufacturer’s recommendations. A dissociation curve was generated at the end of each PCR reaction to verify the amplification of a single product. Identical PCR conditions were performed using 1 μg of cDNA, and the relative expression levels of genes were normalized to the endogenous housekeeping gene Glyceraldehyd 3-phosphate Dehydrogenase GAPDH. The relative mRNA expression level was determined using the 2-ΔΔCt analysis method. Table 1 presents the primers used for real-time RT-PCR.

**Statistical analysis**

The obtained data were analyzed in SPSS V. 20. The normal distribution of the data was examined by the Shapiro-Wilk test, and the non-parametric equivalent of One-Way Analysis of Variances (ANOVA). The Kruskal-Wallis test was used to assess the significance of the results. The study values were expressed as Mean±SEM and P<0.05 was considered as the level of significance in all comparisons.

**Histology**

The animals were deeply anesthetized, decapitated, and their brains were removed and fixed in formalin. The place of cannulae and injection needle were verified by histological examination. For this purpose 100 μm thick sections were taken, and cannulae and needle traces were examined for each side with light microscopy. Only the obtained data from the animals whose cannulae and injections were in the lateral ventricles were used for analysis.

**Results**

**Effect of STZ on IR and GSK-3β expression in the hippocampus**

Using qRT-PCR, we determined the expression level of the IR and GSK-3β genes in the hippocampus, 10 days after ICV injection of STZ. As shown in Figures...
STZ treatment increased the expression of GSK3β; while EGCG treatment after STZ reversed the expression of GSK3β (Kruskal-Wallis test; *P≤0.05 in comparison to control; #P≤0.05 in comparison to STZ group; ## P<0.01 in comparison to STZ group).

1 and 2, two STZ injections in the ventricles led to a significant (P<0.05) upregulation in both the GSK-3β and IR mRNA levels compared to the untreated rats. The enhancing effect of ICV STZ treatment on GSK-3β gene expression was much more than its influence on IR expression.

Catechin treatment decreased IR, but not GSK-3β expression in the hippocampus.

CAT gavage for 10 successive days did not affect GSK-3β mRNA content in the intact rats or the STZ-treated ones (Figure 1), but it could prevent the IR overexpression induced by ICV STZ treatment. CAT gavage significantly (P<0.05) reduced the IR gene expression in comparison to the ICV STZ-injected rats (Figure 2).

EGCG treatment decreased IR and GSK-3β expression in the hippocampus.

- **Table 1.** Primer sequences used in real-time PCR

| Gene   | Primer Sequences (5’ to 3’)                          | Primer Length (bp) |
|--------|------------------------------------------------------|--------------------|
| GSK-3β | Forward: 5’-GAGCTGATCTTTGGAGCCAC-3’                 | 20                 |
|        | Reverse: 5’-CCAACTGTACCCACACACGATGTC-3’             |                    |
| IR     | Forward: 5’-CAGCTGAAAAGGCTACAGG-3’                  | 20                 |
|        | Reverse: 5’-TCCCTTACATCGATGCCTTC-3’                 |                    |
| GAPDH  | Forward: 5’-TGGCTCTTAAAAGGAGCCACAG-3’               | 20                 |
|        | Reverse: 5’-TGAGAGGAGGCATGTCATG-3’                  |                    |

Discussion

The present study was designed to evaluate the effect of CAT and EGCG on IR and GSK-3β expression in the model of dementia, which could further elucidate the impact of oxidative stress in AD pathophysiology. Our results in other studies showed memory impairment after two sets of STZ injections (3 mg/kg). The administration of ICV STZ is characterized by progressive deterioration of memory, cerebral glucose, and energy metabolism that leads to cognitive dysfunction [29, 30]. STZ enters the cells via the Glucose Transporter-2 GLUT-2, which is most abundant in the limbic system [31]. Insulin reduces tau phosphorylation by inhibition...
of GSK-3β via the PI3-K pathway [32]. Therefore, disturbance in insulin signaling cascade leads to an increase in tau hyperphosphorylation potentiating and the formation of NFT [26].

Prolonged consumption of green tea extract, rich in CAT, could also prevent age-related biochemical and morphological changes in the rat hippocampal formation [33]. Prolonged CAT administration prevented either age-related reductions of Postsynaptic Density proteins (PSD-95) and Ca2+/calmodulin-dependent protein kinase II, suggesting that synaptic structural changes may also be involved in its mechanism of action [34].

Many reports suggest that Aβ formation is a protective response to oxidative stress [35]. An initial free radical-induced injury would exacerbate a vicious cycle in which the amyloidogenic processing of APP would be further enhanced, generating more Aβ that, in turn, would cause more oxidative stress [36]. CAT supplementation could significantly decrease lipid peroxidation, H2O2 generation, and protein carbonyl contents in tamoxifen-induced oxidation, which could explain, at least in part, the memory-improving effect of CAT [27, 37].

Emerging evidence has suggested that insulin signaling cascade alters gene expression that is required for long-term memory consolidation [23]. Insulin dysfunction, which occurs in AD leads to GSK-3β activation, which in turn phosphorylates tau and reduces its affinity for microtubules and thereby potentiating NFT formation [38]. Training-induced upregulation of IR mRNA is reported in the Corna Amnumus (CA1) region of hippocampus [39]. Agrawal R, et al. reported a significant decrease in IR mRNA and protein level in CA3 region of hippocampus after ICV STZ treatment [39]. Our data showed a significant increase in IR mRNA in STZ-treated rats, which was reversed by CAT gavage and EGCG administration. This event could be caused by our mRNA sampling, extracted from the whole hippocampus. Osmnovic J, et al. showed a significant increase in IR mRNA content in the hippocampus of ICV treated STZ rats after two weeks, which was not accompanied by a change in protein expression [40]. Agrawal R, et al. showed that IR levels in the CA1 and Dentate Gyrus (DG) regions remained unchanged after ICV STZ injection [39].

Our results demonstrated a significant increase in GSK-3β mRNA after STZ treatment, which is consistent with expected sporadic AD pathogenesis, namely, tau hyperphosphorylation, NFT and amyloid formation [41]. However, CAT did not reverse its overexpression, but EGCG could reverse it. Other reports indicate that total GSK-3β mRNA did not change shortly after ICV STZ injection, but an acute activation of this enzyme occurs as early as 2 weeks after ICV STZ treatment [40]. Decreased phosphor- to total- (p/t) GSK-3β is reported by others up to 1 month after STZ injection. Although the expression of tau in the hippocampus is reported to increase even 2 weeks after ICV STZ treatment, the p/t tau ratio remains unchanged until 1 month, which may be because of the activation of Protein Phosphates 2A (PP2A), the major tau phosphatase [40, 42, 43].

Conclusion

The results of this study emphasize that CAT treatment could reduce IR expression induced by ICV STZ, while it did not reverse GSK3β. Therefore CAT treatment could affect insulin signaling by preventing alterations in IR, but not GSK-3β mRNA expression induced by ICV STZ treatment. On the other hand, EGCG could reverse IR and GSK3β expression, which increased by STZ. Thus it can be hypothesized that the neuroprotective activity of EGCG might be due to its influence on IR and GSK3β expression.

Ethical Considerations

Compliance with ethical guidelines

The study protocol was approved by the Ethics Committee of Qom University of Medical Sciences (No. 91281). All study procedures were in compliance with the ethical guidelines of the Declaration of Helsinki 2013.

Funding

This study was funded by a grant from Qom University of Medical Sciences (Grant number: 91281), Qom, Iran.

Authors contributions

Design of the study: Kambiz Rohampour; Data gathering: Marzieh Zamani, Masoumeh Dolati, Naser Kalhor; Initial draft: Marzieh Zamani, Samira Rashtiani; Writing, revision, and editing the article, and final approval of the study: All authors.

Conflict of interest

The authors declared no conflict of interest.
References

[1] Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, et al. The alzheimer’s disease neuroimaging initiative: A review of papers published since its inception. Alzheimers Dement. 2012; 8(1 Suppl):S1-68. [DOI:10.1016/j.jalz.2011.09.172] [PMID] [PMCID]

[2] Mayeux R. Early alzheimer’s disease. N Engl J Med. 2010; 362(23):2194-201. [DOI:10.1056/NEJMc0910236] [PMID]

[3] Braak H, Braak E. Evolution of Alzheimer’s disease related cortical lesions. In: Gertz HJ, Arendt T, editors. Alzheimer’s Disease - From Basic Research to Clinical Applications. Vienna: Springer; 1998. P. 97-106. (Journal of Neural Transmission. Supplementa; vol 54). [DOI:10.1007/978-3-7091-7508-8_9] [PMID]

[4] Butterfield DA, Reed T, Newman SF, Sultana R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer’s disease and mild cognitive impairment. Free Radic Biol Med. 2007; 43(5):658-77. [DOI:10.1016/j.freeradbiomed.2007.05.037] [PMID] [PMCID]

[5] Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A. 2008; 105(49):19318-23. [DOI:10.1073/pnas.0804571105] [PMID] [PMCID]

[6] Hayashi T, Shishido N, Nakayama K, Nunomura A, Smith MA. Challenging the amyloid cascade hypothesis: Senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann NY Acad Sci. 2004; 1019(1):1-4. [DOI:10.1196/annals.1297.001]

[7] Pannala AS, Rice-Evans CA, Halliwell B, Singh S. Inhibition of peroxynitrite-mediated tyrosine nitration by catechin polyphenols. Biochem Biophys Res Commun. 1997; 232(1):164-8. [DOI:10.1006/bbrc.1997.6254] [PMID]

[8] Ye X, Tai W, Zhang D. The early events of Alzheimer’s disease pathology: From mitochondrial dysfunction to BDNF axonal transport deficits. Neurobiol Aging. 2012; 33(6):1122. [DOI:10.1016/j.neurobiolaging.2011.11.004] [PMID]

[9] Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A. 2008; 105(49):19318-23. [ DOI:10.1073/pnas.0804571105] [PMID] [PMCID]

[10] Wang X, Su B, Fujioka H, Zhu X. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer’s disease patients. Am J Pathol. 2008; 172(2):470-82. [DOI:10.2353/ajpath.2008.071208] [PMID] [PMCID]

[11] Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitro- treated proteins in Alzheimer’s disease brain. J Neurochem. 2003; 85(6):1394-401. [DOI:10.1046/j.1471-4159.2003.01786.x] [PMID]

[12] Mayeux R, Mandel S, Amit T, Youdim MB. Neurological mechanisms of green tea polyphenols in Alzheimer’s and Parkinson’s diseases. J Nutr Biochem. 2004; 15(9):506-16. [DOI:10.1016/j.jnutbio.2004.05.002] [PMID]

[13] Weisburger JH, Chung FL. Mechanisms of chronic disease causation by nutritional factors and tobacco products and their prevention by tea polyphenols. Food Chem Toxicol. 2002; 40(8):1145-54. [DOI:10.1016/S0278-6915(02)00444-5] [PMID]

[14] Nobre Júnior HV, Cunha GM, Maia FD, Oliveira RA, Moraes MO, Rao VS. Catechin attenuates 6-hydroxydopamine (6-OHDA)-induced cell death in primary cultures of mesencephalic cells. Comp Biochem Physiol C Toxicol Pharmacol. 2003; 136(2):175-80. [DOI:10.1016/S1532-0456(03)00198-4]

[15] Zhao WQ, Chen H, Quon MJ, Alkon DL. Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol. 2004; 490(1-3):71-81. [DOI:10.1016/j.ejphar.2004.02.045] [PMID]

[16] Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitro- treated proteins in Alzheimer’s disease brain. J Neurochem. 2003; 85(6):1394-401. [DOI:10.1046/j.1471-4159.2003.01786.x] [PMID]

[17] Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature. 1995; 378(6559):785-9. [DOI:10.1038/378785a0] [PMID]

[18] Choi DY, Lee YJ, Hong JT, Lee HJ. Antioxidant properties of natural polyphenols and their therapeutic potentials for Alzheimer’s disease. Brain Res Bull. 2012; 87(2-3):144-53. [DOI:10.1016/j.brainresbull.2011.11.014] [PMID]

[19] Amin MA, Perry G, Smith MA. Challenging the amyloid cascade hypothesis: Senile plaques and amyloid-beta as protective adaptations to Alzheimer disease. Ann NY Acad Sci. 2004; 1019(1):1-4. [DOI:10.1196/annals.1297.001]

[20] Unger J, McNeill TH, Mosley RT, White M, Moss A, Livingston JN. Distribution of insulin receptor-like immunoreactivity in the rat forebrain. Neuroscience. 1989; 31(1):143-57. [DOI:10.1016/0306-4522(89)90036-5] [PMID]

[21] Zhang D. The early events of Alzheimer’s disease pathology: From mitochondrial dysfunction to BDNF axonal transport deficits. Neurobiol Aging. 2012; 33(6):1122. [DOI:10.1016/j.neurobiolaging.2011.11.004] [PMID]

[22] Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y, et al. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A. 2008; 105(49):19318-23. [DOI:10.1073/pnas.0804571105] [PMID] [PMCID]

[23] Wang X, Su B, Fujioka H, Zhu X. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer’s disease patients. Am J Pathol. 2008; 172(2):470-82. [DOI:10.2353/ajpath.2008.071208] [PMID] [PMCID]

[24] Castegna A, Thongboonkerd V, Klein JB, Lynn B, Markesbery WR, Butterfield DA. Proteomic identification of nitro- treated proteins in Alzheimer’s disease brain. J Neurochem. 2003; 85(6):1394-401. [DOI:10.1046/j.1471-4159.2003.01786.x] [PMID]

[25] de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: Relevance to Alzheimer’s disease. J Alzheimers Dis. 2005; 7(1):45-61. [DOI:10.3233/JAD-2005-7106] [PMID]
[26] Cheng CM, Tseng V, Wang J, Wang D, Matyakhina L, Bondy CA. Tau is hyperphosphorylated in the insulin-like growth factor-I null brain. Endocrinology. 2005; 146(12):5086-91. [DOI:10.1210/en.2005-0063] [PMID]

[27] Parvez S, Tabassum H, Rehman H, Banerjee BD, Athar M, Raisuddin S. Catechin prevents tamoxifen-induced oxidative stress and biochemical perturbations in mice. Toxicology. 2006; 225(2-3):109-18. [DOI:10.1016/j.tox.2006.05.009] [PMID]

[28] Paxinos G, Watson C. The rat brain in stereotaxic coordinates. New York: Academic Press; 1986.

[29] Grünblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem. 2007; 101(3):757-70. [DOI:10.1111/j.1471-4159.2006.04368.x] [PMID]

[30] Lannert H, Hoyer S. Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci. 1998; 112(5):1199-208. [DOI:10.1037/0735-7044.112.5.1199] [PMID]

[31] Arluison M, Quignon M, Nguyen P, Thorens B, Leloup C, Penicaud L. Distribution and anatomical localization of the glucose transporter 2 (GLUT2) in the adult rat brain—an immunohistochemical study. J Chem Neuroanat. 2004; 28(5):117-36. [DOI:10.1016/j.jchemneu.2004.05.009] [PMID]

[32] Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, et al. Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer’s disease. FASEB J. 2004; 18(7):902-4. [DOI:10.1096/fj.03-0978fje] [PMID]

[33] Zhang L, Zhao B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX. Processing of Alzheimer’s amyloid precursor protein during H2O2-induced apoptosis in human neuronal cells. Biochem Biophys Acta. 2005; 1703(2):149-56. [DOI:10.1016/j.bbapap.2004.10.014] [PMID]

[34] Zhang L, Zhao B, Yew DT, Kusiak JW, Roth GS. Processing of Alzheimer’s amyloid precursor protein during H2O2-induced oxidative stress and neurotoxicity. Biochim Biophys Acta. 2005; 1703(2):149-56. [DOI:10.1016/j.bbapap.2004.10.014] [PMID]

[35] Zamani M, Rohampour K, Zeraati M, Hosseinmardi N, Kazemian MM. Pre-training Catechin gavage prevents memory impairment induced by intracerebroventricular streptozotocin in rats. Neurosciences (Riyadh). 2015; 20(3):225-9. [DOI:10.17712/res.2015.3.20140440] [PMID] [PMCID]

[36] Hong M, Lee VM. Insulin and insulin-like growth factor-I regulate tau phosphorylation in cultured human neurons. J Biol Chem. 1997; 272(31):19547-53. [DOI:10.1074/jbc.272.31.19547] [PMID]

[37] Agrawal R, Tyagi E, Shukla R, Nath C. Insulin receptor signaling in rat hippocampus: A study in STZ (ICV) induced memory deficit model. Eur Neuropsychopharmacol. 2011; 21(7):261-7. [DOI:10.1016/j.euroneuro.2010.11.009] [PMID]

[38] Osmanovic Barilar J, Knezovic A, Grünblatt E, Riederer P, Salkovic-Petrisic M. Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer’s disease. J Neural Transm. 2015; 122(4):565–76. [DOI:10.1007/s00702-014-1323-y] [PMID]

[39] Correia SC, Santos RX, Perry G, Zhu X, Moreira PI, Smith MA. Insulin-resistant brain state: The culprit in sporadic Alzheimer’s disease? Ageing Res Rev. 2011; 10(2):264-73. [DOI:10.1016/j.arr.2011.01.001] [PMID] [PMCID]

[40] Deng Y, Li B, Liu Y, Iqbal K, Grundke-Iqbal I, Gong CX. Dysregulation of insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: Implication for Alzheimer’s disease. Am J Pathol. 2009; 175(5):2089-98. [DOI:10.2353/ajpath.2009.090157] [PMID] [PMCID]

[41] Plattner F, Angelo M, Giese KP. The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem. 2006; 281(35):25457-65. [DOI:10.1074/jbc.M603469200] [PMID]